Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QGE031 in Peanut Allergy
NCT01451450Phase 2Withdrawn
- Sponsor
- Novartis
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of ligelizumab in peanut allergy, sponsored by Novartis. Status: withdrawn.
02
Drugs
ligelizumab
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT01451450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01451450.